York Charles N II's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Aug 17, 2022
- Accession no.
- 0001209191-22-046482
- Filed
- Aug 17, 2022
- Trade date
- Aug 15-16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $26.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| York Charles N IICIK 0001655962 | Officer (COO, CFO and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2022 | Common Stock | MOption exerciseAcquired | +4,125 | $0.00 | $0 | 325,490 | Direct | |
| Aug 16, 2022 | Common Stock | SSaleDisposed | −1,089 | $24.31 | −$26,473.59 | 324,401 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2022 | Common Stock | MOption exerciseDisposed | −4,125 | $0.00 | $0 | 17,875 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.